Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123519) titled 'A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases' on Aug. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.
Condition:
Systemic Lupus Erythematosus (SLE)
Lupus Nephritis (LN)
Sjogren'
s Syndrome (SS)
Inflammatory Myopathy
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Antiphospholipid Syndrome (APS)
Intervention:
Drug: YTS109 cell
Recruitment Status: Not recruiting
Phase: Phase 1
Date o...